United Therapeutics (UTHR) Competitors $300.65 +2.77 (+0.93%) As of 10:09 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock UTHR vs. ALNY, BIIB, INCY, NBIX, EXEL, BMRN, EXAS, HALO, MDGL, and RGENShould you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. United Therapeutics vs. Its Competitors Alnylam Pharmaceuticals Biogen Incyte Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Exact Sciences Halozyme Therapeutics Madrigal Pharmaceuticals Repligen United Therapeutics (NASDAQ:UTHR) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations. Does the media prefer UTHR or ALNY? In the previous week, Alnylam Pharmaceuticals had 27 more articles in the media than United Therapeutics. MarketBeat recorded 38 mentions for Alnylam Pharmaceuticals and 11 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.38 beat Alnylam Pharmaceuticals' score of 0.66 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 15 Very Positive mention(s) 7 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Is UTHR or ALNY more profitable? United Therapeutics has a net margin of 40.44% compared to Alnylam Pharmaceuticals' net margin of -11.49%. United Therapeutics' return on equity of 19.33% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets United Therapeutics40.44% 19.33% 16.73% Alnylam Pharmaceuticals -11.49%-510.31%-6.48% Which has better earnings & valuation, UTHR or ALNY? United Therapeutics has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnited Therapeutics$2.88B4.71$1.20B$25.0612.00Alnylam Pharmaceuticals$2.25B19.02-$278.16M-$2.09-156.95 Do analysts prefer UTHR or ALNY? United Therapeutics presently has a consensus price target of $383.08, indicating a potential upside of 27.41%. Alnylam Pharmaceuticals has a consensus price target of $347.75, indicating a potential upside of 6.01%. Given United Therapeutics' higher possible upside, analysts plainly believe United Therapeutics is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score United Therapeutics 0 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.69Alnylam Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 22 Buy rating(s) 0 Strong Buy rating(s) 2.81 Do institutionals & insiders believe in UTHR or ALNY? 94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 10.3% of United Therapeutics shares are owned by insiders. Comparatively, 1.2% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, UTHR or ALNY? United Therapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. SummaryUnited Therapeutics beats Alnylam Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UTHR vs. The Competition Export to ExcelMetricUnited TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.56B$2.49B$5.61B$9.42BDividend YieldN/A1.80%4.01%4.02%P/E Ratio12.009.2228.3620.00Price / Sales4.71580.60414.8086.63Price / Cash10.32165.2635.9658.29Price / Book2.085.088.425.73Net Income$1.20B$30.99M$3.24B$258.18M7 Day Performance0.84%3.09%4.13%3.46%1 Month Performance4.98%14.27%12.22%14.30%1 Year Performance-10.72%-1.13%34.98%18.46% United Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UTHRUnited Therapeutics4.9847 of 5 stars$300.66+0.9%$383.08+27.4%-10.4%$13.56B$2.88B12.001,305Positive NewsUpcoming EarningsALNYAlnylam Pharmaceuticals4.0353 of 5 stars$315.75+0.3%$345.70+9.5%+38.1%$41.17B$2.25B-151.082,230Analyst ForecastBIIBBiogen4.9317 of 5 stars$133.11-0.8%$188.48+41.6%-43.6%$19.50B$9.68B13.147,605Analyst UpgradeINCYIncyte4.5916 of 5 stars$69.98+2.0%$74.47+6.4%+5.7%$13.55B$4.24B218.692,617Upcoming EarningsNBIXNeurocrine Biosciences4.4881 of 5 stars$135.13+1.3%$163.91+21.3%-8.6%$13.37B$2.41B45.811,800Upcoming EarningsAnalyst ForecastEXELExelixis4.8013 of 5 stars$45.58+1.6%$45.22-0.8%+96.8%$12.43B$2.17B20.721,147Analyst ForecastBMRNBioMarin Pharmaceutical4.9877 of 5 stars$58.23+0.2%$93.78+61.1%-30.6%$11.17B$2.85B21.653,040Analyst ForecastAnalyst RevisionEXASExact Sciences4.7674 of 5 stars$54.30+4.6%$70.50+29.8%+3.5%$10.24B$2.76B-9.857,000Positive NewsHALOHalozyme Therapeutics4.8487 of 5 stars$57.65+0.9%$62.50+8.4%+5.9%$7.10B$1.02B15.33390News CoveragePositive NewsMDGLMadrigal Pharmaceuticals4.2692 of 5 stars$319.87+1.4%$420.63+31.5%+9.2%$7.10B$180.13M-17.7290News CoverageInsider TradeRGENRepligen4.617 of 5 stars$121.33-6.8%$170.75+40.7%-11.9%$6.82B$650.43M-269.621,778Upcoming EarningsAnalyst UpgradeAnalyst Revision Related Companies and Tools Related Companies ALNY Alternatives BIIB Alternatives INCY Alternatives NBIX Alternatives EXEL Alternatives BMRN Alternatives EXAS Alternatives HALO Alternatives MDGL Alternatives RGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UTHR) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UTHR Stock Alerts